Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The use of intravitreal antivascular endothelial growth factor (anti-VEGF) injection is gaining wide acceptance as an off-label therapy for diseases that may affect pregnant women. However, these drugs may cause systemic side effects in the mother and fetal harm. This could lead specialists to not administer the drug or women to abort the fetus or to refuse treatment during pregnancy. We report the course of pregnancy in 3 women treated with intravitreal bevacizumab and provide a review of the literature on the use of intravitreal anti-VEGF in pregnancy. Our patients did not have any drug-related adverse event and delivered healthy full-term infants, although one of the women had risk factors for miscarriage. Infants reached all developmental milestones appropriately during infancy. A literature search on the use of intravitreal anti-VEGF injection in pregnancy was undertaken. Data for this review were identified by searches of PubMed and references from relevant articles using the search terms "pegaptanib," "bevacizumab," "ranibizumab," "aflibercept," "anti-VEGF," "intravitreal injection," "pregnant," "pregnancy," "abortion," "miscarriage," "preeclampsia," "embryo-fetal toxicity," "fetal malformations," "teratogenesis," "adverse events," and "maternofetal complications" in multiple combinations. We believe that intravitreal anti-VEGF can be given during pregnancy only when potential benefit to the woman justifies the potential risks to the fetus. When making a decision about whether to give drugs during pregnancy, it is important to consider the timing of exposure and its relationship to windows of developmental sensitivity. We believe that this review will be useful to specialists to inform and possibly treat their pregnant patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of early loss of pregnancy
Wilcox, A. J., Weinberg, C. R., O'Connor, J. F., Baird, D. D., Schlatterer, J. P., Canfield, R. E., Armstrong, E. G., & Nisula, B. C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807283190401 · Cited by 2,354
Cited by
Feig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., & Sanghera, R. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.038 · Cited by 344
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297
Sarvepalli, S. M., Bailey, B. A., D'Alessio, D., Lemaitre, M., Vambergue, A., Rathinavelu, J., & Hadziahmetovic, M. (2023) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.14168 · Cited by 24
Metadata
- Authors
- Polizzi, S., & Mahajan, V. B.
- Venue
- Journal of Ocular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2015-12
- Volume
- 31
- Issue
- 10
- Pages
- 605-610
- ISSN
- 1080-7683 (ISSN-L)
- 1557-7732
- OpenAlex
- W1843785930
- Cited by
- 69
- References
- 1
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature. https://app.cochat.ai/papers/10.1089/jop.2015.0056
- The paper
- Polizzi, S., & Mahajan, V. B. (2015). Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2015.0056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.